Literature DB >> 17356254

Hepatitis C in chronic kidney disease: predialysis patients present more severe histological liver injury than hemodialysis patients?

Lara B Lemos1, Renata M Perez, Marcelo M Lemos, Valéria P Lanzoni, Sergio A Draibe, Ivonete S Silva, Antonio Eduardo B Silva, Maria Lucia G Ferraz.   

Abstract

BACKGROUND: The characteristics of hepatitis C virus (HCV) infection in predialysis patients are poorly understood and they could be different from hemodialysis patients. AIMS: To evaluate the demographics, laboratory and histological characteristics of chronic HCV infection in predialysis patients and to compare them with those observed in hemodialysis patients.
METHODS: Thirty-nine predialysis patients with chronic HCV infection were compared to HCV-infected hemodialysis patients (ratio of 1:3) in terms of demographics, laboratory and histological characteristics. The fibrosis progression rate (FPR) was calculated as the ratio between fibrosis stage and duration of infection.
RESULTS: Predialysis patients were older (57 +/- 10 vs. 45 +/- 12 years; p < 0.001), presented a higher proportion of elevated alanine aminotransferase (71.8 vs. 41.0%; p = 0.001) and aspartate aminotransferase (64.1 vs. 26.5%; p < 0.001), a higher proportion of interface hepatitis (66.7 vs. 47%; p = 0.033) and more advanced fibrosis (71.8 vs. 16.2%; p = 0.001). Among patients with estimated duration of infection, predialysis patients presented a longer duration of infection (22 vs. 6 years; p < 0.001) and no difference in FPR was observed between groups (p = 0.692).
CONCLUSION: Although predialysis patients with HCV infection present more severe histological injury than hemodialysis patients, this finding probably reflects a longer duration of infection with no evidence supporting that hepatitis C presents a more aggressive course in this group. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2007        PMID: 17356254     DOI: 10.1159/000100892

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  5 in total

Review 1.  Management of hepatitis C in patients with chronic kidney disease.

Authors:  Roberto J Carvalho-Filho; Ana Cristina C A Feldner; Antonio Eduardo B Silva; Maria Lucia G Ferraz
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

2.  Hepatitis C is less aggressive in hemodialysis patients than in nonuremic patients.

Authors:  Jose Eduardo Trevizoli; Raissa de Paula Menezes; Lara Franciele Ribeiro Velasco; Regina Amorim; Mauro Birche de Carvalho; Liliana Sampaio Mendes; Columbano Junqueira Neto; José Roberto de Deus Macedo; Francisco de Assis; Rocha Neves
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-23       Impact factor: 8.237

3.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

4.  Liver biopsy in patients on hemodialysis with hepatitis C virus infection: An important tool.

Authors:  S K Agarwal; S Datta Gupta
Journal:  Indian J Nephrol       Date:  2015 May-Jun

Review 5.  Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5.

Authors:  Chen-Hua Liu; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2022-07-25       Impact factor: 9.029

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.